Imaging Biometrics Secures Second Major Neuro-Oncology Contract of Q3

Imaging Biometrics has secured a new annual subscription agreement with a U.S. healthcare system for its suite of neuro-oncology software. This deal marks the company's second major installation this quarter.

The contract grants the healthcare provider access to the firm's core quantitative imaging products, including IB Neuro, IB Delta T1, and IB FTBx. These tools automate and standardize the analysis of MRI scans to provide clinicians with data on brain tumor physiology and treatment response.

"By standardizing the assessment of tumor physiology and treatment response, our platform helps address some of the most significant challenges in brain tumor management," said Michael Schmainda, CEO of Imaging Biometrics LLC, in a statement.

Scaling Clinical Adoption

This installation follows a period of growth for the company as it integrates its automated analysis tools into standard radiology workflows. The software reduces the variability found in manual tumor assessments, which can complicate the monitoring of patients undergoing chemotherapy or radiation.

"This agreement represents our second major installation of the quarter, reflecting the growing demand for objective, quantitative metrics in neuro-oncology," said Trevor Brown, Chief Executive Officer of Imaging Biometrics Limited.

How IB Software Functions

The Imaging Biometrics suite processes standard MRI inputs to generate perfusion maps and comparative metrics. By moving away from purely visual interpretation, the software provides a numerical basis for determining whether a tumor is shrinking, growing, or exhibiting signs of treatment-related inflammation. This condition is a common diagnostic hurdle known as pseudoprogression.

For healthcare systems, the transition to subscription-based software models allows for the deployment of these analytical tools across multiple hospital sites without the need for additional on-premise hardware infrastructure.